NeuroScientific
BIOPHARMACEUTICALS
ASX:NSB

ASX ANNOUNCEMENT
11 JUNE 2024

NEUROSCIENTIFIC COMPLETES PRE-IND MEETING WITH US FDA ON EMTINB FOR ADVANCED GLAUCOMA

NeuroScientific Biopharmaceuticals Ltd (**ASX:NSB**) (**"NeuroScientific"** or **"the Company"**) is pleased to announce that it has received feedback and guidance from the US Food and Drug Administration (FDA) on its planned non-clinical and clinical development program of EmtinB as a treatment for adults with advanced glaucoma via a pre-Investigational New Drug type B meeting (pre-IND meeting).

The successful completion of the pre-IND meeting with the FDA is an important milestone for NeuroScientific as it provides regulatory clarity around the Company's proposed Phase 1 trial. The Company also received positive feedback from the FDA on its planned IND-enabling studies to further evaluate toxicology, pharmacokinetics and formulation optimisation for intravitreal administration.

NeuroScientific Executive Director, Tony Keating said "We are pleased with the guidance and recommendations that the FDA has provided. The FDA has answered a number of critical questions related to our non-clinical and clinical development program and provided us with a clear understanding of the design for our Phase 1 trial. Furthermore, we confirmed with the FDA, the non-clinical intravitreal administration studies needed to complete an IND application.

We will now use this feedback to determine the optimal next steps in progressing EmtinB towards a first-in-human trial. The FDA feedback is critical to our strategy, and we look forward to providing our shareholders with further updates in due course."

This announcement is authorised by the board of NeuroScientific Biopharmaceuticals Ltd.

-ENDS-

For more information please contact:

Tony Keating
Executive Director
tony@neuroscientific.com
+61 8 6382 1805

Chris Ntoumenopoulos
Chairman
ir@neuroscientific.com
+61 8 6382 1805